You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Claims for Patent: 10,413,569


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,413,569
Title:Microporous zirconium silicate for the treatment of hyperkalemia
Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Inventor(s): Keyser; Donald Jeffrey (Southlake, TX), Guillem; Alvaro F. (Lantana, TX)
Assignee: ZS PHARMA, INC. (Coppell, TX)
Application Number:14/692,287
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,413,569
Patent Claims: 1. A particulate zirconium silicate composition having a uniform microporosity with a pore diameter of about 3 angstroms and exhibiting a selective potassium exchange capacity of at least 1.7 mEq/g and a sodium content below 12% by weight, wherein the zirconium silicate is formula (I): A.sub.pM.sub.xZr.sub.1-xSi.sub.nGe.sub.yO.sub.m (I) where A is a potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof, M is at least one framework metal, wherein the framework metal is hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), terbium (4+) or mixtures thereof, "p" has a value from about 1 to about 20, "x" has a value of 0 or approaching 0, "n" has a value from 1 to about 12, "y" has a value from 0 to about 12, "m" has a value from about 3 to about 36 and 1.ltoreq.n+y.ltoreq.12.

2. The composition of claim 1, wherein the selective potassium exchange capacity is from 1.7 to 4.7 mEq/g.

3. The composition of claim 2, wherein the selective potassium exchange capacity is from 2.7 to 3.7 mEq/g.

4. The composition of claim 1, wherein the zirconium silicate exhibits a sodium content below 9% by weight.

5. The composition of claim 1, wherein the zirconium silicate is ZS-9.

6. The composition of claim 1, wherein the selective potassium exchange capacity is at least 3.5 mEq/g.

7. The composition of claim 1, wherein the selective potassium exchange capacity is at least 4.0 mEq/g.

8. A particulate zirconium silicate composition having a uniform microporosity with a pore diameter of about 3 angstroms and exhibiting a selective potassium exchange capacity of at least 1.7 mEq/g and a sodium content below 12% by weight, wherein the zirconium silicate is formula (I): A.sub.pM.sub.xZr.sub.1-xSi.sub.nGe.sub.yO.sub.m (I) where A is a potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof, M is at least one framework metal, wherein the framework metal is hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), terbium (4+) or mixtures thereof, "p" has a value from about 1 to about 20, "x" has a value of 0 or approaching 0, "n" has a value from 1 to about 12, "y" has a value from 0 to about 12, "m" has a value from about 3 to about 36 and 1.ltoreq.n+y.ltoreq.12, wherein the zirconium silicate in the composition comprises particles having a median particle size of greater than 3 microns and less than 7% of the particles in the composition have a diameter less than 3 microns.

9. The composition of claim 8, wherein the zirconium silicate in the composition exhibits a median particle size of greater than 3 microns and less than 3% of the particles in the composition have a diameter less than 3 microns.

10. A particulate zirconium silicate composition having a uniform microporosity and exhibiting a selective potassium exchange capacity in the range of from 1.7 mEq/g to 3.7 mEq/g and a sodium content below 12% by weight, wherein the zirconium silicate is formula (I): A.sub.pM.sub.xZr.sub.1-xSi.sub.nGe.sub.yO.sub.m (I) where A is a potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof, M is at least one framework metal, wherein the framework metal is hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), terbium (4+) or mixtures thereof, "p" has a value from about 1 to about 20, "x" has a value of 0 or approaching 0, "n" has a value from 1 to about 12, "y" has a value from 0 to about 12, "m" has a value from about 3 to about 36 and 1.ltoreq.+y.ltoreq.12.

11. The composition of claim 10, wherein the zirconium silicate in the composition comprises particles having a median particle size of greater than 3 microns and less than 7% of the particles in the composition have a diameter less than 3 microns.

12. The composition of claim 11, wherein the zirconium silicate in the composition exhibits a median particle size of greater than 3 microns and less than 3% of the particles in the composition have a diameter less than 3 microns.

13. The composition of claim 12, wherein the zirconium silicate is ZS-9.

14. The composition of claim 12, wherein the sodium content is below 9% by weight.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.